| Jun 5 |
Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
|
| Jun 3 |
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
|
| Jun 3 |
Genmab and BioNTech report data from Phase II GCT1046-04 trial for mNSCLC
|
| Jun 2 |
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
|
| Jun 1 |
BioNTech/Genmab lung cancer therapy improves survival with Keytruda
|
| Jun 1 |
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
|
| May 23 |
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
|
| May 22 |
Genmab acquires biotechnology company ProfoundBio in $1.8bn deal
|
| May 21 |
Genmab Completes Acquisition of ProfoundBio
|
| May 15 |
Market Chatter: Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'
|
